National trends in the utilization of robotic-assisted radical cystectomy

An analysis using the Nationwide Inpatient Sample

M. Francesca Monn, K. Clinton Cary, Hristos Kaimakliotis, Chandra K. Flack, Michael Koch

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objectives: To determine temporal and regional trends in utilization of robotic-assisted radical cystectomy (RARC) in the United States and to explore factors associated with utilization of robotic assistance. Materials and methods: Using 2009 to 2011 data from the Nationwide Inpatient Sample, we identified radical cystectomy cases that were performed using either open or robotic assistance and applied Nationwide Inpatient Sample discharge weights to determine national incidence. Univariable and multivariable logistic regressions were performed to assess regional trends and characteristics associated with having RARC. Descriptive analysis was performed using the chi-square test, the Student t test, and the Mann-Whitney U test. Results: Of the 29,719 radical cystectomy patients, 3,733 were RARC (12.6%). Although there was no change in the proportion of RARC performed annually (P = 0.702). Length of stay was 1 day longer for open cystectomy than RARC (P<0.001). On multivariate regression, patients whose primary payer was Medicaid were less likely than private insurance patients to undergo RARC (odds ratio = 0.60, P = 0.074). Additionally, patients in the south were at 50% reduced odds of undergoing RARC (odds ratio = 0.49, P = 0.044). Median hospital costs were $5,000 greater for RARC (P<0.001). Conclusions: Regional variation in utilization should be monitored to ensure equal access to new technology and to assess potential overuse of new technology. Although RARC is associated with higher median hospital costs, further studies to assess its benefits are warranted.

Original languageEnglish
Pages (from-to)785-790
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume32
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Cystectomy
Robotics
Inpatients
Hospital Costs
Odds Ratio
Technology
Medicaid
Chi-Square Distribution
Nonparametric Statistics
Insurance
Length of Stay
Logistic Models
Students

Keywords

  • Radical cystectomy
  • Robotic assistance
  • Urothelial bladder cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{08ce3fc567fb4454a0c58cce54a9859e,
title = "National trends in the utilization of robotic-assisted radical cystectomy: An analysis using the Nationwide Inpatient Sample",
abstract = "Objectives: To determine temporal and regional trends in utilization of robotic-assisted radical cystectomy (RARC) in the United States and to explore factors associated with utilization of robotic assistance. Materials and methods: Using 2009 to 2011 data from the Nationwide Inpatient Sample, we identified radical cystectomy cases that were performed using either open or robotic assistance and applied Nationwide Inpatient Sample discharge weights to determine national incidence. Univariable and multivariable logistic regressions were performed to assess regional trends and characteristics associated with having RARC. Descriptive analysis was performed using the chi-square test, the Student t test, and the Mann-Whitney U test. Results: Of the 29,719 radical cystectomy patients, 3,733 were RARC (12.6{\%}). Although there was no change in the proportion of RARC performed annually (P = 0.702). Length of stay was 1 day longer for open cystectomy than RARC (P<0.001). On multivariate regression, patients whose primary payer was Medicaid were less likely than private insurance patients to undergo RARC (odds ratio = 0.60, P = 0.074). Additionally, patients in the south were at 50{\%} reduced odds of undergoing RARC (odds ratio = 0.49, P = 0.044). Median hospital costs were $5,000 greater for RARC (P<0.001). Conclusions: Regional variation in utilization should be monitored to ensure equal access to new technology and to assess potential overuse of new technology. Although RARC is associated with higher median hospital costs, further studies to assess its benefits are warranted.",
keywords = "Radical cystectomy, Robotic assistance, Urothelial bladder cancer",
author = "Monn, {M. Francesca} and Cary, {K. Clinton} and Hristos Kaimakliotis and Flack, {Chandra K.} and Michael Koch",
year = "2014",
doi = "10.1016/j.urolonc.2014.04.007",
language = "English",
volume = "32",
pages = "785--790",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - National trends in the utilization of robotic-assisted radical cystectomy

T2 - An analysis using the Nationwide Inpatient Sample

AU - Monn, M. Francesca

AU - Cary, K. Clinton

AU - Kaimakliotis, Hristos

AU - Flack, Chandra K.

AU - Koch, Michael

PY - 2014

Y1 - 2014

N2 - Objectives: To determine temporal and regional trends in utilization of robotic-assisted radical cystectomy (RARC) in the United States and to explore factors associated with utilization of robotic assistance. Materials and methods: Using 2009 to 2011 data from the Nationwide Inpatient Sample, we identified radical cystectomy cases that were performed using either open or robotic assistance and applied Nationwide Inpatient Sample discharge weights to determine national incidence. Univariable and multivariable logistic regressions were performed to assess regional trends and characteristics associated with having RARC. Descriptive analysis was performed using the chi-square test, the Student t test, and the Mann-Whitney U test. Results: Of the 29,719 radical cystectomy patients, 3,733 were RARC (12.6%). Although there was no change in the proportion of RARC performed annually (P = 0.702). Length of stay was 1 day longer for open cystectomy than RARC (P<0.001). On multivariate regression, patients whose primary payer was Medicaid were less likely than private insurance patients to undergo RARC (odds ratio = 0.60, P = 0.074). Additionally, patients in the south were at 50% reduced odds of undergoing RARC (odds ratio = 0.49, P = 0.044). Median hospital costs were $5,000 greater for RARC (P<0.001). Conclusions: Regional variation in utilization should be monitored to ensure equal access to new technology and to assess potential overuse of new technology. Although RARC is associated with higher median hospital costs, further studies to assess its benefits are warranted.

AB - Objectives: To determine temporal and regional trends in utilization of robotic-assisted radical cystectomy (RARC) in the United States and to explore factors associated with utilization of robotic assistance. Materials and methods: Using 2009 to 2011 data from the Nationwide Inpatient Sample, we identified radical cystectomy cases that were performed using either open or robotic assistance and applied Nationwide Inpatient Sample discharge weights to determine national incidence. Univariable and multivariable logistic regressions were performed to assess regional trends and characteristics associated with having RARC. Descriptive analysis was performed using the chi-square test, the Student t test, and the Mann-Whitney U test. Results: Of the 29,719 radical cystectomy patients, 3,733 were RARC (12.6%). Although there was no change in the proportion of RARC performed annually (P = 0.702). Length of stay was 1 day longer for open cystectomy than RARC (P<0.001). On multivariate regression, patients whose primary payer was Medicaid were less likely than private insurance patients to undergo RARC (odds ratio = 0.60, P = 0.074). Additionally, patients in the south were at 50% reduced odds of undergoing RARC (odds ratio = 0.49, P = 0.044). Median hospital costs were $5,000 greater for RARC (P<0.001). Conclusions: Regional variation in utilization should be monitored to ensure equal access to new technology and to assess potential overuse of new technology. Although RARC is associated with higher median hospital costs, further studies to assess its benefits are warranted.

KW - Radical cystectomy

KW - Robotic assistance

KW - Urothelial bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=84905254911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905254911&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2014.04.007

DO - 10.1016/j.urolonc.2014.04.007

M3 - Article

VL - 32

SP - 785

EP - 790

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 6

ER -